- Home
- AVIR vs TECX Comparison
AVIR vs TECX Comparison
Compare AVIR & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- TECX
- Stock Information
- Founded
- AVIR 2012
- TECX 2019
- Country
- AVIR United States
- TECX United States
- Employees
- AVIR N/A
- TECX N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- TECX
- Sector
- AVIR Health Care
- TECX
- Exchange
- AVIR Nasdaq
- TECX Nasdaq
- Market Cap
- AVIR 273.0M
- TECX 334.4M
- IPO Year
- AVIR 2020
- TECX 2018
- Fundamental
- Price
- AVIR $3.73
- TECX $22.19
- Analyst Decision
- AVIR Hold
- TECX Buy
- Analyst Count
- AVIR 1
- TECX 5
- Target Price
- AVIR $6.00
- TECX $79.20
- AVG Volume (30 Days)
- AVIR 398.9K
- TECX 237.5K
- Earning Date
- AVIR 08-06-2025
- TECX 08-13-2025
- Dividend Yield
- AVIR N/A
- TECX N/A
- EPS Growth
- AVIR N/A
- TECX N/A
- EPS
- AVIR N/A
- TECX N/A
- Revenue
- AVIR N/A
- TECX N/A
- Revenue This Year
- AVIR N/A
- TECX N/A
- Revenue Next Year
- AVIR N/A
- TECX N/A
- P/E Ratio
- AVIR N/A
- TECX N/A
- Revenue Growth
- AVIR N/A
- TECX N/A
- 52 Week Low
- AVIR $2.46
- TECX $13.70
- 52 Week High
- AVIR $4.15
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- AVIR 74.60
- TECX 54.15
- Support Level
- AVIR $3.63
- TECX $20.39
- Resistance Level
- AVIR $3.78
- TECX $22.01
- Average True Range (ATR)
- AVIR 0.14
- TECX 1.18
- MACD
- AVIR 0.02
- TECX 0.15
- Stochastic Oscillator
- AVIR 100.00
- TECX 92.82
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.